BioCardia, Inc. Q3 2025 Earnings Recap

BioCardia delivered solid progress in Q3, advancing its innovative cardiac therapies and engaging in constructive regulatory discussions that may accelerate market entries in both the U.S. and Japan.

Key Takeaways

• Received FDA breakthrough designation for CardiAmp therapy, aimed at treating ischemic heart failure, enhancing its expeditious approval pathway.
• Demonstrated strong preliminary results from the chronic myocardial ischemia trial, with 60% of patients showing significant improvements in exercise tolerance and angina reduction.
• Actively enrolling in the CardioAmp HF2 Phase III trial, with centers reporting rapid patient recruitment and anticipated reimbursements from CMS for both treated and control groups.